During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using combination immunotherapy for metastatic melanoma in the second article of a 2-part series.
Health Professionals
Nivolumab Plus Relatlimab Fails to Improve RFS in Resected Stage III/IV Melanoma
Nivolumab plus relatlimab did not improve recurrence-free survival vs nivolumab in resected stage III/IV melanoma.
Scientists discover the ‘roadmap’ that aggressive cancer uses to spread around the body – identifying ways to block its escape
Image of human melanoma tissue, with melanoma cells in green and purple extracellular matrix fibres arranged perpendicular at the border of the tumour. Credit Oscar Maiques Carlos
Nivolumab/Relatlimab Shows Sustained Efficacy in Advanced Melanoma
Data from RELATIVITY-047 show consistent benefits with nivolumab/relatlimab across most patient subgroups, including those with BRAF-mutated disease.